EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:3395 - carbidopa
| Formula | C10H14N2O4.H2O |
| Net Charge | 0 |
| Average Mass | 244.247 |
| Monoisotopic Mass | 244.10592 |
| SMILES | C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O.O |
| InChI | InChI=1S/C10H14N2O4.H2O/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6;/h2-4,12-14H,5,11H2,1H3,(H,15,16);1H2/t10-;/m0./s1 |
| InChIKey | QTAOMKOIBXZKND-PPHPATTJSA-N |
| Roles Classification |
|---|
| Chemical Role: | Bronsted acid A molecular entity capable of donating a hydron to an acceptor (Brønsted base). |
| Biological Roles: | immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor An EC 4.1.1.* (carboxy-lyase) inhibitor that interferes with the action of aromatic-L-amino-acid decarboxylase (EC 4.1.1.28). analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. dopaminergic agent A drug used for its effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. |
| Applications: | antidyskinesia agent Any compound which can be used to treat or alleviate the symptoms of dyskinesia. immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. ophthalmology drug Any compound used for the treatment of eye conditions or eye diseases. vasoconstrictor agent Drug used to cause constriction of the blood vessels. antihypertensive agent Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism. anti-asthmatic agent Any compound that has anti-asthmatic effects. analgesic An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. antiparkinson drug A drug used in the treatment of Parkinson's disease. dopaminergic agent A drug used for its effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. vulnerary A drug used in treating and healing of wounds. antipsychotic agent Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| carbidopa (CHEBI:3395) has part carbidopa (anhydrous) (CHEBI:39585) |
| carbidopa (CHEBI:3395) has role analgesic (CHEBI:35480) |
| carbidopa (CHEBI:3395) has role anti-asthmatic agent (CHEBI:65023) |
| carbidopa (CHEBI:3395) has role antidyskinesia agent (CHEBI:66956) |
| carbidopa (CHEBI:3395) has role antihypertensive agent (CHEBI:35674) |
| carbidopa (CHEBI:3395) has role antiparkinson drug (CHEBI:48407) |
| carbidopa (CHEBI:3395) has role antipsychotic agent (CHEBI:35476) |
| carbidopa (CHEBI:3395) has role dopaminergic agent (CHEBI:48560) |
| carbidopa (CHEBI:3395) has role EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor (CHEBI:59321) |
| carbidopa (CHEBI:3395) has role immunosuppressive agent (CHEBI:35705) |
| carbidopa (CHEBI:3395) has role ophthalmology drug (CHEBI:66981) |
| carbidopa (CHEBI:3395) has role vasoconstrictor agent (CHEBI:50514) |
| carbidopa (CHEBI:3395) has role vulnerary (CHEBI:73336) |
| carbidopa (CHEBI:3395) is a catechols (CHEBI:33566) |
| carbidopa (CHEBI:3395) is a hydrate (CHEBI:35505) |
| carbidopa (CHEBI:3395) is a hydrazines (CHEBI:24631) |
| carbidopa (CHEBI:3395) is a monocarboxylic acid (CHEBI:25384) |
| IUPAC Name |
|---|
| (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid—water (1/1) |
| INN | Source |
|---|---|
| carbidopa | ChemIDplus |
| Synonyms | Source |
|---|---|
| (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate | ChEBI |
| (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate | ChEBI |
| Carbidopa component of carbilev | ChEMBL |
| Carbidopa component of parcopa | ChEMBL |
| Carbidopa component of sinemet | ChEMBL |
| carbidopa hydrate | ChEBI |
| Brand Names | Source |
|---|---|
| Carbidopa component of corbilta | ChEMBL |
| Carbidopa component of crexont | ChEMBL |
| Carbidopa component of dhivy | ChEMBL |
| Carbidopa component of dopasnap | ChEMBL |
| Carbidopa component of duopa | ChEMBL |
| Carbidopa component of ipx-203 | ChEMBL |
| Citations |
|---|